Company
Regeneron
Regeneron is a biotechnology company that develops and commercializes medicines for treating various diseases, including rare diseases and cancer.
Why it’s in the news: It is in the news due to the expansion of its successful Dupixent partnership, FDA approvals for new drugs, and a new venture into radiopharmaceuticals.
Latest on Regeneron
- STAT+: Sanofi, Regeneron expand partnership after Dupixent success
- STAT+: Pharmalittle: We’re reading about a Regeneron rare disease drug, an Ultragenyx gene therapy, and more
- STAT+: Regeneron drug for disease that causes dangerous bone growth earns FDA approval
- Regeneron wades into radiopharma through $40M upfront deal with Telix
- STAT+: FDA approves Ultragenyx gene therapy
- Fact Sheet President Donald J Trump Announces Deal With Regeneron To Bring Most Favored Na
Connections
7 entities linked to Regeneron across the news graph.
Under pressure from (1)
Also connected to (6)
STAT+: Sanofi, Regeneron expand partnership after Dupixent successSTAT+: Pharmalittle: We’re reading about a Regeneron rare disease drug, an Ultragenyx gene therapy, and moreSTAT+: FDA approves Ultragenyx gene therapySTAT+: Regeneron drug for disease that causes dangerous bone growth earns FDA approvalUnited StatesDonald Trump